NCT03942419: Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression |
|
|
| Recruiting | 3 | 420 | US | Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution | Eyenovia Inc. | Myopia | 06/28 | 06/28 | | |
KEYNOTE-D88, NCT05572684: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 131 | US | NC410, pembrolizumab, KEYTRUDA® | NextCure, Inc., Merck Sharp & Dohme LLC | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 07/25 | 11/25 | | |
NCT03348995: The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration |
|
|
| Active, not recruiting | N/A | 250 | US | Bridge-Enhanced ACL Restoration (BEAR) | Miach Orthopaedics | Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture | 04/24 | 04/34 | | |
